United Therapeutics | UTHR - Interest Expense On Debt


United Therapeutics reported $3.1M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Amarin USD 3K 5K Dec/2024
Ardelyx USD 5.76M 37K Dec/2025
Baxter International USD 58M 14M Sep/2025
Bayer EUR 675M 87M Dec/2025
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Esperion Therapeutics USD 22.64M 585K Dec/2025
Gilead Sciences USD 240M 15M Mar/2026
GlaxoSmithKline GBP 167M 21M Mar/2026
Halozyme Therapeutics USD 5.51M 597K Mar/2026
Insmed USD 20.08M 517K Mar/2026
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
J&J USD 43M 25M Mar/2026
Lexicon Pharmaceuticals USD 2.03M 124K Dec/2025
Moderna USD 11.49B 36B Mar/2026
Omeros USD 4.05M 5.16M Sep/2024
Pfizer USD 671M 40M Mar/2026
PTC Therapeutics USD 2.87B 2.82B Mar/2026
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
Teva Pharmaceutical Industries USD 216M 4M Mar/2026
United Therapeutics USD 3.1M 100K Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025